### TABLE 2. Major clinical studies of blinatumomab in B-cell Acute Lymphoblastic Leukemia

<table>
<thead>
<tr>
<th>Study Data</th>
<th>Patients' Characteristics</th>
<th>Study Outcomes</th>
</tr>
</thead>
</table>
| B-ALL adults, R/R randomized (blinatumomab vs CHEMO), multicenter international, Phase III, TOWER, NCT02013167 (39) | N=405  
Blinatumomab=271, CHEMO=134  
• R ≤ 12 m after CR1 or allo-SCT or refractory in 1st line treatment or ≥R2  
• Only Ph- patients  
• Previous allo-SCT: 104/403 (35%)  
• Median age: 40.9 years-old | Results blinatumomab vs CHEMO:  
• Median OS 7.7m vs 4.0m after median F/U time 11.7m, p=0.01  
• CR/CRh in 44% vs 25%, p<0.001  
• MRD-: 33% vs 12%  
• Median RFS: 7.3m vs 4.6m  
• In both groups, 24% underwent allo-SCT |
| B-ALL adults, R/R, single-arm, multicenter, international, Phase II, NCT01466179, NCT020003612 (38) | N=189  
• R ≤ 12 m after CR1 or allo-SCT or refractory in 1st line treatment or ≥R2  
• Only Ph- patients  
• Previous allo-SCT: 64/189 (34%)  
• Median age: 39 years-old | CR/CRh: 81/189 (43%)  
• MRD- after 2 cycles: 60/181 (33%)  
(1st=59, 2nd=1)  
• Post response allo-SCT: 32/81 (40%)  
After median F/U time 8.9m:  
• In CR/CRh patients: median RFS 5.9m  
(MRD-: 6.9m vs MRD+:2.3m)  
• Median OS (189 patients): 6.1m with median F/U time 9.8m |
| B-ALL adults, R/R, single-arm, multicenter, Germany (GMALL Study Group), Phase I/II NCT01209286 (37) | N=36  
• Only Ph- patients  
• Previous allo-SCT: 15/36 (42%)  
• Median age: 32 years-old | CR/CRh: 25/36 (69%)  
• CR/CRh after allo-SCT: 8/15 (52%)  
• MRD-: 22/36 (61%)  
• Post-response allo-SCT: 13/25 (52%)  
(R=2, TRM=6)  
• without allo-SCT after CR/CRh: 12/25 (48%)  
(R=8)  
After median F/U time 28.9m:  
• 12 patients with CR (RFS 61%)  
• Post-response allo-SCT (N=9): CR=6, R=2, TRM=1 |
| B-ALL adults in CR but with persistent/recurrent MRD, single-arm, multicenter, Germany (GMALL Study Group), Phase II, NCT00198991, NCT00198978 (41,43) | N=20/21  
• Persistent MRD: 15  
• Recurrent MRD: 5  
• Ph+ ALL TKI-resistant: 5  
• No previous allo-SCT  
• Median age 47 years-old | MRD- after 1st cycle: 16/20 (80%)  
3/5 Ph+ ALL achieved response  
allo-SCT, N=9  
After media F/U time 50.8 m:  
• CR: 10 (long-term RFS 50%)  
• Post-response allo-SCT(10): CR=5, R=3, TRM=1  
• without allo-SCT(11): CR=5, R=5, TRM=1 |
| B-ALL adults, R/R, single-arm, multicenter, Phase II, NCT02000427 (ALCANTARA) (74) | N=45  
• Ph+: all patients  
• R/R in ≥2nd generation TKI and/or with intolerance to imatinib  
• ≥18 years-old, median age: 55 years-old  
• Previous allo-SCT: 44%  
• Mutation T315I: 27% | CR/CRh: 36%  
• MRD-: 88% of CR/CRh  
• Median RFS: 6.7m  
• Median OS: 7.1m  
• 44% underwent allo-SCT |

ALL: Acute Lymphoblastic Leukemia, R/R: Relapse/Refractory disease, R: relapse, m: months, N: number of patients, CHEMO: chemotherapy, CR: complete remission, Ph: Philadelphia chromosome, allo-SCT: allogeneic stem cell transplantation, F/U: follow-up, CRh: complete remission without normal complete blood count, MRD: minimal residual disease, RFS: relapse free survival, OS: overall survival, GMALL: German Multistudy Group for Adult Acute Lymphoblastic Leukemia, TRM: treatment related mortality, TKI: tyrosine-kinase inhibitors